



## **Peter F. Lebowitz, M.D., Ph.D.**

*Global Therapeutic Area Head, Oncology*

As Global Therapeutic Area (TA) Head of Oncology at Janssen Research & Development, LLC, Peter has end-to-end responsibility for bringing the best science and medicine together with global world-class drug discovery and development capabilities to deliver transformational therapeutics for oncologic diseases.

Prior to taking on the TA Head role, Peter was Head of Hematologic Malignancies for the TA. In this role, he was responsible for strategic oversight and execution of Janssen's hematologic malignancy drug discovery and development programs. Under his leadership, the Hematologic Malignancies

group built an industry-leading portfolio, which includes approved and investigational products for such conditions as multiple myeloma, myelodysplastic syndromes, multicentric Castleman's Disease and various B cell malignancies.

Before joining Janssen, Peter was Vice President in both early and late-stage clinical development for GlaxoSmithKline, where he successfully filed 10 Investigational New Drugs, played a major role in the global registration of three oncology drugs and led major projects from preclinical discovery through pivotal Phase 3 trials.

Prior to joining the industry, Peter was Assistant Professor of Medicine, Division of Hematology/Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, where he established an independently funded translational and clinical research program and was a Principal Investigator on numerous clinical research trials.

Peter graduated from Harvard University and earned his medical degree and doctorate from the University of Pennsylvania School of Medicine. He then completed his hematology/oncology fellowship at the National Cancer Institute, National Institutes of Health.